Effervescent powder treatment for vitiligo

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a novel effervescent formulation of 5-Fluorouracil for the treatment of localized stable vitiligo. The study aims to enhance the delivery of the drug through a unique effervescent mixture that improves solubility and absorption. Participants will receive either the new effervescent powder or plain 5-Fluorouracil powder to assess the effectiveness of this innovative approach. The trial will include patients aged over 10 years with stable vitiligo lesions for at least one year.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who will be diagnosed as localized stable vitiligo.
* Age older than 10 years
* Stability of lesions for a duration of at least 1 year.
* Patients who didn't receive treatment for vitiligo in the previous 6 weeks before starting the study.
* Patients who agreed to join the study and signed written consent and continued till the end of the follow up period

Exclusion Criteria:

* Patients with vitiligo patches on mucous membrane,
* Patients with Koebner phenomenon,
* Other uncontrolled systemic illnesses
* Patients receiving any systemic or topical treatment for vitiligo

Where it's running

• Facualty of Pharmacy, Al Azhar University
  Cairo, Egypt Recruiting

Study contacts

• Study coordinator: Neveen A. Kohaf, Ph.D
• Email: nevenabdo@azhar.edu.eg
• Phone: +201069482380

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• crisaborole 2% versus tacrolimus 0.1% with light therapy for facial vitiligo

  This study tests whether applying crisaborole 2% ointment can improve stable facial vitiligo in children and adults and whether it is as safe and effective as tacrolimus 0.1% when combined with light therapy.

  Recruiting Phase 3 Cairo University · Cairo · NCT07904910

• Imaging vitiligo lesions with polarized, sub-ultraviolet, and ultraviolet dermoscopy

  This study tests whether advanced light-based skin imaging can reveal details of vitiligo spots in adults more clearly than standard polarized dermoscopy.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07846969

• MH004 Ointment in non-segmental vitiligo: a phase 3 trial

  A 12-month randomized trial tests MH004 ointment to see if it helps facial vitiligo more than a placebo in people aged 12 to 75.

  Recruiting Phase 3 Minghui Pharmaceutical (Hangzhou) Ltd · Beijing, Beijing Municipality · NCT07682506

• NSV: Vitiligo Drug Safety and Effectiveness Registry for Adults and Teens

  This registry tracks adults and teens with nonsegmental vitiligo to see how usual treatments work and how safe they are over time in real-world dermatology care.

  Recruiting CorEvitas · Waltham, Massachusetts · NCT07659418

• D-2570 in Non-Segmental Vitiligo (Phase 2)

  This study tests whether D-2570 can improve skin discoloration in adults with non-segmental vitiligo compared with a placebo.

  Recruiting Phase 2 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07625891

• LY4005130 for adults with non-segmental vitiligo

  This study will test whether intravenous LY4005130 is safe and what side effects it may cause in adults with non-segmental vitiligo.

  Recruiting at 35 sites Phase 2 Eli Lilly and Company · Phoenix, Arizona and 34 other locations · NCT07533019

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.